BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 26347105)

  • 21. Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.
    Lambertini M; Boni L; Michelotti A; Magnolfi E; Cogoni AA; Mosconi AM; Giordano M; Garrone O; Arpino G; Poggio F; Cinacchi P; Bighin C; Fregatti P; Pronzato P; Blondeaux E; Del Mastro L;
    J Natl Cancer Inst; 2022 Mar; 114(3):400-408. PubMed ID: 34850043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection of ovarian function by GnRH agonists during chemotherapy: a meta-analysis.
    Sun X; Dongol S; Jiang J; Kong B
    Int J Oncol; 2014 Apr; 44(4):1335-40. PubMed ID: 24535045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis.
    Bedaiwy MA; Abou-Setta AM; Desai N; Hurd W; Starks D; El-Nashar SA; Al-Inany HG; Falcone T
    Fertil Steril; 2011 Mar; 95(3):906-14.e1-4. PubMed ID: 21145541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
    Choi MC; Chung YS; Lee JW; Kwon BS; Park BK; Kim SI; Shim SH; Lee KB; Seong SJ; Lee SJ; Lee SH; Yoo HJ; Song T; Kim MK; Baek MH; Kang S; Kim YM
    Eur J Cancer; 2020 Jul; 133():56-65. PubMed ID: 32442924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis.
    Elgindy E; Sibai H; Abdelghani A; Mostafa M
    Obstet Gynecol; 2015 Jul; 126(1):187-95. PubMed ID: 26241272
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 'An ounce of prevention is worth a pound of cure': the case for and against GnRH-agonist for fertility preservation.
    Blumenfeld Z; Katz G; Evron A
    Ann Oncol; 2014 Sep; 25(9):1719-1728. PubMed ID: 24651411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis.
    Vitek WS; Shayne M; Hoeger K; Han Y; Messing S; Fung C
    Fertil Steril; 2014 Sep; 102(3):808-815.e1. PubMed ID: 25044080
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
    Gerber B; von Minckwitz G; Stehle H; Reimer T; Felberbaum R; Maass N; Fischer D; Sommer HL; Conrad B; Ortmann O; Fehm T; Rezai M; Mehta K; Loibl S;
    J Clin Oncol; 2011 Jun; 29(17):2334-41. PubMed ID: 21537042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fertility after treatment for Hodgkin's disease.
    Blumenfeld Z; Dann E; Avivi I; Epelbaum R; Rowe JM
    Ann Oncol; 2002; 13 Suppl 1():138-47. PubMed ID: 12078896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy.
    Blumenfeld Z; Shapiro D; Shteinberg M; Avivi I; Nahir M
    Lupus; 2000; 9(6):401-5. PubMed ID: 10981642
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.
    Badawy A; Elnashar A; El-Ashry M; Shahat M
    Fertil Steril; 2009 Mar; 91(3):694-7. PubMed ID: 18675959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
    Chlebowski RT; Pan K; Col NF
    Breast Cancer Res Treat; 2017 Jan; 161(2):185-190. PubMed ID: 27785653
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis.
    Shen YW; Zhang XM; Lv M; Chen L; Qin TJ; Wang F; Yang J; Liu PJ; Yang J
    Onco Targets Ther; 2015; 8():3349-59. PubMed ID: 26622183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Premature ovarian failure after chemotherapy for breast cancer].
    Mathelin C; Brettes JP; Diemunsch P
    Bull Cancer; 2008 Apr; 95(4):403-12. PubMed ID: 18495569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis.
    Azim HA; Shohdy KS; Kaldas DF; Kassem L; Azim HA
    Curr Probl Cancer; 2020 Dec; 44(6):100592. PubMed ID: 32527567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of gonadotropin-releasing hormone agonists for ovarian preservation in patients receiving cyclophosphamide for systemic lupus erythematosus: A meta-analysis.
    Ejaz K; Abid D; Juneau P; Chu J; Hasni S
    Lupus; 2022 Dec; 31(14):1706-1713. PubMed ID: 36148853
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study.
    Lambertini M; Fontana V; Massarotti C; Poggio F; Dellepiane C; Iacono G; Abate A; Miglietta L; Ferreccio C; Pescio MC; Conte B; Blondeaux E; Bighin C; D'Alonzo A; Vaglica M; Zanardi E; Boccardo F; Ballestrero A; Anserini P; Del Mastro L
    Breast; 2018 Oct; 41():51-56. PubMed ID: 30007268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women.
    Lu YS; Wong A; Kim HJ
    Front Oncol; 2021; 11():700722. PubMed ID: 34595110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.